|
|
Vaccine Detail
|
Hybrid Membrane Vesicle (MV) Vaccine: Pam₂-MUC1 + Autologous Membrane Proteins |
| Vaccine Information |
- Vaccine Name: Hybrid Membrane Vesicle (MV) Vaccine: Pam₂-MUC1 + Autologous Membrane Proteins
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Zhou et al., 2025)
-
Adjuvant:
QS-21; GAP112 (TLR4 agonist) (Zhou et al., 2025)
- Immunization Route: subcutaneous injection
- Description: A dual-antigen subunit vaccine combining synthetic palmitoylated MUC1 glycopeptide (Pam₂-MUC1, 13 μg/dose) with autologous tumor-derived membrane proteins (25 μg/dose) extracted from surgically resected B16-MUC1 melanoma tumors via freeze-thaw cycles and centrifugation, formulated as extracellular vesicle-mimicking liposomes (~200 nm, DOPC/cholesterol) and co-adjuvanted with QS-21 (5 μg) and GAP112 (5 μg), a structurally simplified TLR4 agonist. Three vaccine formulations were compared: synthetic antigen alone with adjuvants (P+G+Q), autologous membrane proteins with adjuvants (M+G+Q), and the dual-antigen combination with adjuvants (P+M+G+Q). In therapeutic postoperative recurrence prevention settings, mice received three subcutaneous vaccinations on days 2, 4, and 6 following 90% tumor resection. The dual-antigen/dual-adjuvant formulation (P+M+G+Q) achieved 3.9-fold increases in anti-MUC1 IgG titers and 2.8-fold increases in anti-membrane protein IgG titers by day 42 compared to adjuvant-free controls (P+M), with significantly elevated IFN-γ⁺TNF-α⁺ double-positive CD4⁺ and CD8⁺ T cells, upregulated DC costimulatory molecules (CD80/CD86), and generation of central (CD44⁺CD62L⁺) and effector (CD44⁺CD62L⁻) memory T-cell populations. Tumor volumes remained <400 mm³ in the P+M+G+Q group versus >1500 mm³ in controls by day 12 post-surgery with significantly extended survival and potent CTL activity. GAP112 and QS-21 synergistically induced 5811 pg/mL IL-6 from macrophages (vs 3313 pg/mL GAP112 alone), validating GAP112 as a cost-effective MPLA alternative. Cross-reactivity demonstrated that P+G+Q effectively recognized autologous membrane protein antigens, while M+G+Q could not recognize the specific MUC1 peptide target, confirming the complementary nature of the dual-antigen approach. Platform validated across three tumor models (B16-MUC1, EAC with Pam₂-MG3, B16-OVA with OVA peptide) with comparable immune activation profiles and no observed toxicity in vitro or in vivo (Zhou et al., 2025).
|
| Host Response |
|
|
| References |
Zhou et al., 2025: Zhou SH, Lei YJ, Wen Y, Ding D, Luo MQ, Cui HY, Guo J. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. Journal of controlled release : official journal of the Controlled Release Society. 2025; 385; 113979. [PubMed: 40570966].
|
|
